<?xml version="1.0" encoding="UTF-8"?>
<ref id="B13">
 <label>13</label>
 <mixed-citation publication-type="journal">
  <person-group person-group-type="author">
   <name>
    <surname>Mir</surname>
    <given-names>O</given-names>
   </name>
   <name>
    <surname>Boudou-Rouquette</surname>
    <given-names>P</given-names>
   </name>
   <name>
    <surname>Larousserie</surname>
    <given-names>F</given-names>
   </name>
   <name>
    <surname>Babinet</surname>
    <given-names>A</given-names>
   </name>
   <name>
    <surname>Dumaine</surname>
    <given-names>V</given-names>
   </name>
   <name>
    <surname>Anract</surname>
    <given-names>P</given-names>
   </name>
   <etal/>
  </person-group>. 
  <article-title>Objective response to sorafenib in advanced clear-cell sarcoma</article-title>. 
  <source>Ann Oncol</source> (
  <year>2012</year>) 
  <volume>23</volume>:
  <page-range>807–9</page-range>.  
  <pub-id pub-id-type="doi">10.1093/annonc/mds005</pub-id>
 </mixed-citation>
</ref>
